Many molecular and clinical studies suggest that HER2 and hormone receptor positive breast cancers have the ability to switch between hormonal-driven and ErbB-driven signalling, with this switch mediating therapeutic resistance. This evidence concerns the gene NR4A1 and breast carcinoma.